Back to UBS Group AG UBS Group AG

GANXGANX
22 quarters

Position history for UBS Group AGUBS Group AG's holdings in GAIN THERAPEUTICS INC

UBS Group AG holds 215,012 shares of GANX (GAIN THERAPEUTICS INC), worth $436,475 as of 2026-Q2. The position was decreased (-2.5% shares). GANX represents 0.0% of UBS Group AG's portfolio.

Current Value

$436,475

Current Shares

215,012

Total Value Change

+$345,475

Total Shares Change

+208,907

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2026-Q2
Latest
Decreased
215,012
-2.5%
$436,4750.0%$2.03
0
2026-Q1
Increased
220,489
+171.8%
$427,7490.0%$2.63
39
2025-Q4
Decreased
81,121
-42.3%
$261,2100.0%$3.05
0
2025-Q3
Increased
140,677
+331.1%
$248,9980.0%$1.81
25
2025-Q2
Decreased
32,635
-24.7%
$58,7430.0%$1.97
0
2025-Q1
Increased
43,360
+23.1%
$82,8180.0%$1.89
18
2024-Q4
Increased
35,227
+316.6%
$76,0900.0%$2.18
23
2024-Q3
Decreased
8,455
-26.0%
$15,0500.0%$1.99
0
2024-Q2
Increased
11,422
+31.7%
$14,6200.0%$1.28
16
2024-Q1
Decreased
8,673
-38.1%
$32,6970.0%$3.77
0
2023-Q4
Increased
14,023
+68.9%
$45,7860.0%$3.27
21
2023-Q3
Decreased
8,304
-12.1%
$27,2370.0%$3.28
0
2023-Q2
Increased
9,447
+119.4%
$42,3220.0%$4.50
22
2023-Q1
Decreased
4,305
-40.9%
$20,7500.0%$4.71
0
2022-Q4
Increased
7,289
+76.8%
$22,8150.0%$3.13
20
2022-Q3
Decreased
4,122
-35.7%
$13,0000.0%$3.17
0
2022-Q2
Increased
6,411
+56.4%
$23,0000.0%$3.59
18
2022-Q1
Decreased
4,100
-60.9%
$17,0000.0%$4.09
0
2021-Q4
Increased
10,497
+55.7%
$57,0000.0%$5.30
20
2021-Q3
Increased
6,740
+64.4%
$51,0000.0%$7.65
20
2021-Q2
Decreased
4,100
-32.8%
$41,0000.0%$10.20
0
2021-Q1
New
6,105
-
$91,0000.0%$14.66
33

Other major holders of GANX: GREENLIGHT CAPITAL INC, Gotham Asset Management, LLC, MARSHALL WACE, LLP

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used